Case Report: SARS-CoV-2 Infection—Are We Redeemed? A Report of Candida Spondylodiscitis as a Late Complication

Moreno-Gómez, Luis Miguel; Esteban-Sinovas, Olga; García‐Pérez, Daniel; García-Posadas, Guillermo; Delgado-Fernández, Juan; Paredes, Igor

doi:10.3389/fmed.2021.751101

Cited by 4 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to PRISMA diagram, the cases with fungal aethiology and the repots with bacterial SD and/or epidural abscess diagnosed over 12 weeks post-COVID-19 were excluded. [ 24 , 25 , 26 , 27 , 28 , 29 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

Post-COVID-19 Spondylodiscitis: A Case Study and Review of the Literature

et al. 2023

View full text Add to dashboard Cite

COVID-19 is currently a major health problem, leading to respiratory, cardiovascular and neurological complications, with additional morbidity and mortality. Spinal infections are rare, representing around 1% of all bone infections and comprising less than 2 per 10,000 of all hospitalizations in tertiary care centers. Spondylodiscitis is a complex disease, with challenging diagnosis and management. We report the case of a 45-year-old man, non-smoker hospitalized for severe COVID-19 disease with respiratory failure. Post-COVID-19, in the 8th week after discharge, he was diagnosed by magnetic resonance imaging with spondylodiscitis, but etiology was not confirmed by microbiological investigations. Antibiotics were used, considering the identification of MRSA from cultures of pleural fluid and nasal swab, but surgical intervention was not provided. Clinic, biologic and imagistic were improved, but rehabilitation and long term follow up are necessary. We concluded that spondylodiscitis with spinal abscess is a rare but severe complication post-COVID-19 disease, due to dysbalanced immune response related to the respiratory viral infection, endothelial lesions, hypercoagulation and bacterial superinfection.

show abstract

Section: Discussionmentioning

confidence: 99%

Post-COVID-19 Spondylodiscitis: A Case Study and Review of the Literature

et al. 2023

View full text Add to dashboard Cite

show abstract

Candida spondylodiscitis: a systematic review and meta-analysis of seventy two studies

Adelhoefer,

Gonzalez,

Bedi

et al. 2023

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

Objectives Knowledge of Candida spondylodiscitis is limited to case reports and smaller case series. Controversy remains on the most effective diagnostical and therapeutical steps once Candida is suspected. This systematic review summarized all cases of Candida spondylodiscitis reported to date concerning baseline demographics, symptoms, treatment, and prognostic factors. Methods A PRISMA-based search of PubMed, Web of Science, Embase, Scopus, and OVID Medline was performed from database inception to November 30, 2022. Reported cases of Candida spondylodiscitis were included regardless of Candida strain or spinal levels involved. Based on these criteria, 656 studies were analyzed and 72 included for analysis. Kaplan-Meier curves, Fisher’s exact, and Wilcoxon’s rank sum tests were performed. Results In total, 89 patients (67% males) treated for Candida spondylodiscitis were included. Median age was 61 years, 23% were immunocompromised, and 15% IV drug users. Median length of antifungal treatment was six months, and fluconazole (68%) most commonly used. Thirteen percent underwent debridement, 34% discectomy with and 21% without additional instrumentation. Median follow-up was 12 months. The two year survivorship free of death was 80%. The two year survivorship free of revision was 94%. Younger age (p = 0.042) and longer length of antifungal treatment (p = 0.061) were predictive of survival. Conclusion Most patients affected by Candida spondylodiscitis were males in their sixties, with one in four being immunocompromised. While one in five patients died within two years of diagnosis, younger age and prolonged antifungal treatment might play a protective role.

show abstract

Antibacterials/antifungals/hydroxychloroquine

2022

Reactions Weekly

View full text Add to dashboard Cite

Case Report: SARS-CoV-2 Infection—Are We Redeemed? A Report of Candida Spondylodiscitis as a Late Complication

Cited by 4 publications

References 32 publications

Post-COVID-19 Spondylodiscitis: A Case Study and Review of the Literature

Post-COVID-19 Spondylodiscitis: A Case Study and Review of the Literature

Candida spondylodiscitis: a systematic review and meta-analysis of seventy two studies

Antibacterials/antifungals/hydroxychloroquine

Contact Info

Product

Resources

About